Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04221893 · ClinicalTrials.gov registry record · NA
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
A NA study of Stage IV Gastric Cancer and Stage IV Esophageal Adenocarcinoma, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- NA
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT04221893: Recruiting NA study of Stage IV Gastric Cancer and Stage IV Esophageal Adenocarcinoma, sponsored by University of California, San Francisco.
NCT04221893 is a NA study of Stage IV Gastric Cancer and Stage IV Esophageal Adenocarcinoma that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 28 participants, below the 55-participant average among 5 other Stage IV Gastric Cancer trials with a reported enrollment target (49% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04221893, a NA study of Stage IV Gastric Cancer and Stage IV Esophageal Adenocarcinoma, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. This trial is being done to determine if giving radiation therapy to patients who are being treated with immunotherapy and whose cancers are progressing (getting worse) can slow or stop the growth of their cancers. It may also help researchers determine if giving radiation therapy to one tumor can stimulate the immune system to attack other tumors in the body that are not targeted by the radiation therapy.
Primary Outcome
Proportion of patients who achieve as their best overall response according to Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1 criteria: Stable disease (SD), partial response (PR), confirmed Complete Response (CR), or progressive disease (PD). Corresponding exact confidence intervals will be reported for the entire cohort and stratified by histologic subtype, programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) status, microsatellite instability (MSI), and organs
Conditions Studied
Interventions
- RADIATION Radiation Therapy (RT)
Study Locations (2)
California
- University of California, San Francisco - San Francisco
- John Muir Medical Center-Walnut Creek - Walnut Creek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2020-08-07 |
| Est. Completion | 2028-04-30 |
| Phase | NA |
What NCT04221893 shows while recruiting
NCT04221893 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 55-participant average among 5 other Stage IV Gastric Cancer trials with a reported enrollment target (49% lower).
The record links to 10 conditions, with Stage IV Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which Radiation Therapy (RT) is the first listed.
NCT04221893 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04221893 about?
NCT04221893 is a clinical study titled "Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers". This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. This trial is being done to determine if giving rad...
What is the current status of trial NCT04221893?
This trial is currently recruiting. It is a NA study. The enrollment target is 28 participants. The study started on 2020-08-07. Estimated completion is 2028-04-30.
What conditions does trial NCT04221893 study?
This clinical trial studies the following conditions: Stage IV Gastric Cancer, Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Adenocarcinoma of the Gastroesophageal Junction, Stage IVA Esophageal Adenocarcinoma.
What interventions are being tested in trial NCT04221893?
The interventions under investigation include: Radiation Therapy (RT) (RADIATION).
Who is sponsoring clinical trial NCT04221893?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04221893 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
COMPLETED · Phase 2
-
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
COMPLETED · Phase 2
-
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
COMPLETED · Phase 2
-
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI